Research Paper Accepted for Publication: Discordant Breast and Axillary Pathologic Response to NAC

After months of hard work, dedication, and rigorous research, our team has reached a significant milestone - our research paper, Discordant Pathologic Response in the Breast and Axilla to Neoadjuvant Chemotherapy, has been accepted for publication in the prestigious academic journal "Annals of Surgical Oncology".

The use of neoadjuvant chemotherapy (NAC) has increased over time due to its effectiveness in turning inoperable tumors operable, reducing the morbidity of surgery, de-escalating surgery, and functioning as a prognostic tool. Although the use of NAC is the cornerstone treatment for patients diagnosed with node-positive breast cancer, we observed that there is a particular group whose primary breast tumor responds while the nodal disease does not, which we have termed as a discordant response. In our manuscript, Discordant Pathologic Response in the Breast and Axilla to Neoadjuvant Chemotherapy, we identified patient demographic factors and clinicopathologic implications that promote a discordant response between breast and axillary nodes after NAC.